Keloid Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The keloid treatment market size is expected to increase from USD 8.74 billion in 2025 to USD 9.10 billion in 2026 and reach USD 11.15 billion by 2031, growing at a CAGR of 4.15% over 2026-2031. This report is Segmented by Treatment Type (Intralesional Corticosteroids, 5-FU Based, Silicone Based, Cryotherapy, Surgical Excision, Laser, Radiation, Others), Route of Administration (Injectable, Topical, Procedural/Device Based), End User (Hospitals, Dermatology Clinics, Ascs, Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, MEA, and South America). Forecasts in Value (USD).

Global Keloid Treatment Market Trends and Insights

Rising Preference For Multimodal Keloid Therapy

The keloid treatment market is shifting from single-modality care as recurrence control becomes as critical as short-term lesion reduction. A 2026 systematic review assessing 162 studies found that treatment plans combining intralesional corticosteroids, surgical excision, laser modalities, and radiotherapy delivered stronger and more durable outcomes than single-modality approaches. This shift increases revenue per treated episode by distributing spending across drugs, procedures, and follow-up visits. A 2025 network meta-analysis reported that Triamcinolone acetonide (TAC) combined with 5-Fluorouracil and pulsed-dye laser achieved a relative risk of 2.98 compared with TAC monotherapy, supporting broader adoption of bundled treatment protocols.

Expanding Use Of Intralesional Corticosteroid And 5-FU Combination

The keloid treatment market is benefiting from a clear shift toward corticosteroid and 5-Fluorouracil (5-FU) combinations in settings that support repeat injection protocols. A 2024 systematic review and meta-analysis covering 15 studies found that corticosteroid plus 5-FU delivered stronger patient and observer assessments, greater scar height reduction, and fewer adverse effects, such as hypopigmentation, skin atrophy, and telangiectasia, than corticosteroid-only treatment. This finding supports escalation from low-cost monotherapy to a regimen that improves visible outcomes and tolerability. It also creates a practical market split, with higher-resource clinics adopting combination care and cost-sensitive systems continuing to rely more heavily on steroid-only injections.

High Recurrence Rates After Monotherapy

High recurrence after single-modality treatment remains a key constraint in the keloid treatment market. A European cohort study (2025) of 206 patients found that patients treated with triamcinolone acetonide (TAC) injections and laser therapy had significantly higher recurrence rates, with TAC reporting χ² = 21.9 and p < 0.001. This limits confidence in low-intensity treatment pathways and increases the likelihood of patients moving through multiple regimens before achieving durable disease control. Repeat visits also reduce care delivery efficiency when they do not result in sustained outcome improvements. In lower-resource settings, where combination care remains less available, this creates a structural ceiling on therapeutic success within the keloid treatment market. Until providers adopt more consistent recurrence-control protocols, the market will continue to record uneven outcomes across regions and provider types.

Other drivers and restraints analyzed in the detailed report include:

• Growing Adoption Of Post-Excision Adjuvant Radiotherapy
• Increasing Availability Of Laser-Assisted Delivery And Advanced Equipment
• Access Constraints For Radiation And Device-Based Care In Smaller Markets

Segment Analysis

Intralesional corticosteroids held 28.12% of the keloid treatment market share in 2025, making them the largest treatment segment by revenue. Their position reflected strong clinical familiarity, low acquisition cost, and broad use across hospital and outpatient settings. The segment continues to benefit from established workflows, as clinicians can administer steroid injections without specialized capital equipment. However, the market is shifting away from steroid monotherapy as stronger clinical evidence supports combination regimens for longer-lasting disease control.

A 2025 network meta-analysis showed that combinations involving Triamcinolone acetonide (TAC), 5-Fluorouracil, and laser modalities outperformed monotherapy approaches, supporting protocol migration in high-volume centers. This shift explains why 5-Fluorouracil-based therapy is forecast to expand at the fastest CAGR of 5.53% through 2031 within this segment. Clinicians increasingly use it as the pharmacological backbone of combination regimens rather than only as an alternative injectable. Silicone-based therapy remains important for prevention-oriented use, especially after surgery and in patients for whom repeated injections are less suitable.

Complete Report Scope:

• By Treatment Type
  • Intralesional Corticosteroids
  • 5-Fluorouracil Based Therapy
  • Silicone Based Therapy
  • Cryotherapy
  • Surgical Excision With Adjuvant Therapy
  • Laser Therapy
  • Radiation Therapy
  • Other Treatment Types
• By Route Of Administration
  • Injectable
  • Topical
  • Procedural Or Device Based
• By End User
  • Hospitals
  • Dermatology Clinics
  • Ambulatory Surgical Centers
  • Specialty Clinics
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America is expected to account for 41.56% of the keloid treatment market share in 2025, making it the largest regional contributor. The United States is projected to drive this position through its strong dermatology infrastructure, broad procedural availability, and higher per-patient spending on specialist care. The region benefits from an established mix of pharmacological, laser-based, and adjuvant approaches, supporting broader treatment adoption across the care pathway. Canada also supports early commercialization of novel topical options, and BirchBioMed’s expected approval in Canada in February 2026 highlights the region’s role in differentiated product launches.

Asia-Pacific is expected to be the fastest-growing region, with the keloid treatment market size projected to increase at a CAGR of 8.56% through 2031. Elevated genetic susceptibility across several Asian populations, expanding private dermatology networks, and rising focus on scar appearance outcomes after surgery or injury support this growth. South Korea and Japan lead in technology adoption, while China adds scale through its large urban patient pool and expanding dermatology clinic chains. A 2025 multi-ancestry study expected to identify 26 susceptibility loci reinforces the region’s importance for targeted identification and treatment planning.

Europe is expected to hold the third-largest position in 2025, with Germany, the United Kingdom, France, Italy, and Spain contributing most of the regional revenue. The European keloid treatment market reflects a cautious treatment approach, supporting continued use of silicone-led and conservative management pathways. The Middle East and Africa remain underpenetrated despite a high underlying burden, mainly due to limited treatment infrastructure across several countries. South America shows steady growth, with larger countries gradually adopting combination care as dermatology services expand.

List of Companies Covered in this Report:

• 3M
• Alliance Pharma plc
• AVITA Medical, Inc.
• Bausch Health
• Biodermis LLC
• Candela Medical
• CCA Industries, Inc.
• Cutera
• Galderma Group AG
• HRA Pharma
• Johnson & Johnson
• Lumenis
• Merz Pharma GmbH and Co. KGaA
• Molnlycke Health Care
• Newmedical Technology Inc.
• Perrigo Company
• Scar Heal Inc.
• Sensus Healthcare, Inc.
• Smiths Group
• Sonoma Pharmaceuticals
• Stratpharma AG

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support